COVID-19 Archives - Page 14 of 16

Markets

WB cuts Neuronetics to market perform

William Blair downgraded Neuronetics (NASDAQ:STIM) to “market perform,” citing added uncertainty from COVID-19 headwinds and a commercial restructuring. The stock was quoted at $2.20, down 16 cents, in afternoon trading...

May 5, 2020

Developments

Aridis Pharma enrolls first COVID-19 patient in ongoing Phase 3 trial

Aridis Pharmaceuticals (NASDAQ:ARDS) enrolled the first COVID-19 patient in its ongoing Phase 3 trial of AR-301 for ventilator-associated pneumonia. Initiated in the first quarter of 2019, the Phase 3 study will assess...

May 4, 2020

Developments

Athersys opens first clinical site for Phase 2/3 COVID-19-induced ARDS trial

Athersys (NASDAQ:ATHX) and University Hospitals Cleveland Medical Center have opened the first clinical site for a Phase 2/3 study evaluating MultiStem cell therapy for COVID-19-induced acute respiratory distress...

May 1, 2020

Developments

Eiger doses first COVID-19 patients with peginterferon lambda

Eiger BioPharmaceuticals (NASDAQ:EIGR) dosed the first patients in its Phase 2 study of peginterferon lambda for the treatment of mild COVID-19. The study will enroll some 120 patients who will receive either a single...

April 30, 2020

Developments

Capricor reports all six COVID-19 patients treated with CAP-1002 have survived

Capricor Therapeutics (NASDAQ:CAPR) reported that all six critical COVID-19 patients who were treated with CAP-1002, an allogeneic cardiac cell therapy, have survived. The six COVID-19 patients, who were admitted to...

April 29, 2020

Markets

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

H.C. Wainwright more than doubled the price target for Arcturus Therapeutics (NASDAQ:ARCT) to $62 from $26, citing impressive preclinical results from its COVID-19 vaccine candidate. Shares of Arcturus jumped $7.96, to...

April 28, 2020

Feature

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device is helping to open a new front in the battle against COVID-19. “Optimal volume management and knowledge of capillary status is key to survivability...

April 28, 2020

Developments

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), submitted an IND application to the FDA to conduct a Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is a...

April 24, 2020

Developments

Mesoblast cell therapy posts 83% survival in COVID-19 ARDS patients

Mesoblast (NASDAQ:MESO; ASX:MSB) reported an 83% survival in 10-of-12, or 83%, of ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated during March-April 2020...

April 24, 2020

Markets

BTIG ups Centogene PT to $23 from $18

BTIG raised its price target for Centogene (NASDAQ:CNTG) to $23 from $18, citing a “solid execution” in its pharma and diagnostics segments in 2019. The stock closed at $18.69 on April 23. Analyst Sung Ji Nam writes...

April 24, 2020

Tag - COVID-19

WB cuts Neuronetics to market perform

Aridis Pharma enrolls first COVID-19 patient in ongoing Phase 3 trial

Athersys opens first clinical site for Phase 2/3 COVID-19-induced ARDS trial

Eiger doses first COVID-19 patients with peginterferon lambda

Capricor reports all six COVID-19 patients treated with CAP-1002 have survived

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

Mesoblast cell therapy posts 83% survival in COVID-19 ARDS patients

BTIG ups Centogene PT to $23 from $18

General

More